These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18720537)

  • 21. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis.
    Duseja A; Nanda M; Das A; Das R; Bhansali A; Chawla Y
    Trop Gastroenterol; 2004; 25(1):15-7. PubMed ID: 15303464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
    Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
    F1000Res; 2020; 9():56. PubMed ID: 32595949
    [No Abstract]   [Full Text] [Related]  

  • 23. Cryptogenic cirrhosis and NAFLD: are they related?
    Maheshwari A; Thuluvath PJ
    Am J Gastroenterol; 2006 Mar; 101(3):664-8. PubMed ID: 16464222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.
    Unger LW; Herac M; Staufer K; Salat A; Silberhumer G; Hofmann M; Trauner M; Rasoul-Rockenschaub S; Soliman T; Reiberger T; Berlakovich GA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):309-316. PubMed ID: 27922486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
    Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
    Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
    Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence and harm of nonalcoholic fatty liver disease].
    Shao YL; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic liver disease in diabetes mellitus.
    Amarapurkar D; Das HS
    Trop Gastroenterol; 2002; 23(1):3-5. PubMed ID: 12170918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptogenic cirrhosis in the region where obesity is not prevalent.
    Kojima H; Sakurai S; Matsumura M; Umemoto N; Uemura M; Morimoto H; Tamagawa Y; Fukui H
    World J Gastroenterol; 2006 Apr; 12(13):2080-5. PubMed ID: 16610061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.
    De Luca-Johnson J; Wangensteen KJ; Hanson J; Krawitt E; Wilcox R
    Dig Dis Sci; 2016 Sep; 61(9):2710-20. PubMed ID: 27262844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study.
    Mohammed OK; Mahadeva S
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1423-8. PubMed ID: 25867030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
    Bugianesi E; Leone N; Vanni E; Marchesini G; Brunello F; Carucci P; Musso A; De Paolis P; Capussotti L; Salizzoni M; Rizzetto M
    Gastroenterology; 2002 Jul; 123(1):134-40. PubMed ID: 12105842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.
    Rinaldi L; Nascimbeni F; Giordano M; Masetti C; Guerrera B; Amelia A; Fascione MC; Ballestri S; Romagnoli D; Zampino R; Nevola R; Baldelli E; Iuliano N; Rosato V; Lonardo A; Adinolfi LE
    World J Gastroenterol; 2017 Feb; 23(8):1458-1468. PubMed ID: 28293093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD 2017 Cirrhosis Collaborators
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):245-266. PubMed ID: 31981519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis.
    Thuluvath PJ; Hanish S; Savva Y
    Transplantation; 2018 Apr; 102(4):656-663. PubMed ID: 29215462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for nonalcoholic steatohepatitis in cryptogenic cirrhosis.
    Leite AB; Mattos AA; Mattos AZ; Coral GP; Evaldt S
    Arq Gastroenterol; 2012 Dec; 49(4):245-9. PubMed ID: 23329217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Liver cirrhosis in diabetes mellitus; a complication not always recognized].
    Thewissen CM; Tiebosch AT; Kloppenburg WD; Haagsmna EB; Hoogenberg K
    Ned Tijdschr Geneeskd; 2008 Nov; 152(44):2369-74. PubMed ID: 19055132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis.
    Valery PC; McPhail S; Stuart KA; Hartel G; Clark PJ; O'Beirne J; Skoien R; Rahman T; Moser C; Powell EE
    Intern Med J; 2021 May; 51(5):691-698. PubMed ID: 32096890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
    Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
    Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.